Founded in 1981, Purolite is a leading manufacturer of ion exchange media, polymeric adsorbents, catalysts and advanced polymers. Headquartered in Bala Cynwyd, PA., the company has manufacturing facilities in the USA, China, Romania and the UK, and operates dedicated R&D centers in the USA, China, Romania, Russia and the UK. Purolite has a network of over 40 offices in over 30 countries to provide customers with easy access to the largest technical sales and support network in the industry.
Started in 2012, Purolite Life Sciences supports R&D and production-scale applications in pharmaceuticals, food production, bioprocessing, fine chemical and other markets. Its portfolio includes high-quality resins for enzyme immobilization, adsorption, extraction, and chromatography, and finished products for biocatalysis. For over 25 years, Purolite resins and adsorbents have been used in drug formulations as active pharmaceutical ingredients (APIs) and excipients from its FDA inspected facility. Purolite is the only globally-active company that focuses its R&D investment exclusively on advanced resin technology. In addition to perfecting existing products, Purolite aim to discover new products for new applications, by developing products that address specific challenges that customers face.
In an effort to clarify resin choices and highlight two popular options, we talked to Dr. Alessandra Basso, Business Development Manager for the Lifetech™ and Chromalite® product ranges and Hans J. Johansson, Global Applications Director both at Purolite Life Sciences about the most frequently asked questions for resin selection between agarose and methacrylic and what each is best suited for....Continued
Combining Ion Exchange and Reverse Phase Chromatography for Highly Efficient and Cost Effective Peptide Purification
The combination of using a low pressure ion exchange step (50-100 micron) with standard reverse phase (12-18 micron) polishing was demonstrated using Chromalite® PCG1200FS and Chromalite® 15AD2. This resulted in a peptide purification process that was more cost-effective than the traditional two-step reverse phase process. The is because the low pressure ion exchange step is much more cost effective than the reverse phase step. This novel process permitted bivalirudin purification from a semi-crude feed of 80% purity to greater than 99% purity with greater than 90% recovery....Continued
Technologies like the Praesto® Jetted A50 resin and novel approaches for the chromatography step provide the flexibility needed to meet the increasing demands placed on downstream processing. These novel approaches have been shown to provide increased productivity, decreased buffer consumption and lower cost for consumables. These strategies and others will be needed to meet the evolving demands for mAb manufacturing and enable more efficient use of both existing and future downstream facilities....Continued
A one-time evaluation is not sufficient in that any changes that a supplier might make in their source, their production process, or a myriad of other items could impact the raw material quality and thus would impact drug manufacturing and ultimately could impact drug availability to patients. Thus, raw materials require continuous monitoring using a drug life cycle approach....Continued
Over the past decade Purolite has developed and introduced proprietary ‘jetting’ technology for continuous manufacturing of uniform particle size synthetic polymer beads. This innovative manufacturing process removes the need for extensive and costly screening and improves yields significantly....Continued
Pre-activated Resins for Ligand Immobilization to Facilitate the Creation of Customized Affinity Purification Media
To enable the development of customized affinity purification media, Purolite has recently launched three pre-activated resins for ligand immobilization. The resins, Praesto NHS, Praesto CNBr, and Praesto Epoxy and are well suited for research, diagnostic and academic applications and are available in three particle sizes - 45μm, 65μm and 90μm....Continued
Lowering MAb Clinical Trial Material Manufacturing Costs with Purpose-designed Protein A Chromatography Resins – A Case Study
The use of Protein A affinity chromatography is commonplace in biopharmaceutical manufacturing, with 95% of all commercially available MAbs using Protein A purification. High purity is achieved in one step (around 99%), but it is ... Continued
Purpose-designed Protein A resins for Improved Downstream Process and Cost Efficiency in MAb purification
Data in the poster compares the use of Praesto AC with the market-leading agarose Protein A resin and finds that approximately 50% savings can be achieved in small scale manufacturing by using Praesto AC in pre-packed columns....Continued